[HTML][HTML] Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma
M Bai, M Wang, T Deng, Y Bai, K Zang… - Cancer Biology & …, 2022 - ncbi.nlm.nih.gov
Objective: The mainstay treatment of esophageal squamous cell carcinoma (ESCC) involves
chemotherapy and immunotherapy. However, alternative therapies are required for patients …
chemotherapy and immunotherapy. However, alternative therapies are required for patients …
A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell …
J Huang, Y Liu, T Wu, Z Liu, J Zhou, Y Yuan, M Yang… - 2023 - ascopubs.org
4029 Background: Esophageal cancer is one of the most common cancers worldwide with
esophageal squamous cell carcinoma (ESCC) being the predominant histological subtype …
esophageal squamous cell carcinoma (ESCC) being the predominant histological subtype …
70O Randomized, global, phase III study of tislelizumab (TIS)+ chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal …
K Kato, H Yoon, E Raymond, R Hubner… - Annals of …, 2022 - annalsofoncology.org
Background TIS, an anti-PD-1 antibody,+ chemo as 1L therapy demonstrated statistically
significant and clinically meaningful improvement in overall survival (OS) vs placebo (PBO)+ …
significant and clinically meaningful improvement in overall survival (OS) vs placebo (PBO)+ …
1514P Randomized, global, phase III study of tislelizumab (TIS)+ chemotherapy (chemo) vs placebo (PBO)+ chemo as first-line (1L) treatment for advanced/metastatic …
R Hubner, J Xu, K Kato, E Raymond, Y Shu… - Annals of …, 2023 - annalsofoncology.org
Background At interim analysis (IA) of RATIONALE-306 (NCT03783442), 1L TIS+ chemo
demonstrated a statistically significant, clinically meaningful improvement in overall survival …
demonstrated a statistically significant, clinically meaningful improvement in overall survival …
SHR‐1316, an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study
L Mu, Y Song, K Zhao, Y Liu, Q Fan, X Wang… - Thoracic …, 2021 - Wiley Online Library
Background This multicentre, open‐label study evaluated the efficacy and safety of
antiprogrammed death ligand 1 antibody SHR‐1316 plus liposomal irinotecan and 5 …
antiprogrammed death ligand 1 antibody SHR‐1316 plus liposomal irinotecan and 5 …
O-15 randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in …
J Ajani, F El Hajbi, D Cunningham… - Annals of …, 2021 - annalsofoncology.org
Background The global Phase 3 study RATIONALE 302 (NCT03430843) evaluated the
efficacy and safety of second-line tislelizumab, an anti-PD-1 antibody, in patients with …
efficacy and safety of second-line tislelizumab, an anti-PD-1 antibody, in patients with …
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized …
L Shen, K Kato, SB Kim, JA Ajani, K Zhao… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Patients with advanced or metastatic esophageal squamous cell carcinoma
(ESCC) have poor prognosis. For these patients, treatment options are limited after first-line …
(ESCC) have poor prognosis. For these patients, treatment options are limited after first-line …
ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated …
R Xu, H Luo, J Lu, Y Bai, T Mao, J Wang, Q Fan… - 2021 - ascopubs.org
4000 Background: The current standard first-line therapy for advanced or metastatic ESCC
is doublet chemotherapy, and prognosis remains poor. Camrelizumab, a humanized anti-PD …
is doublet chemotherapy, and prognosis remains poor. Camrelizumab, a humanized anti-PD …
Phase II multicenter trial: first-line immunochemotherapy with or without radiotherapy in metastatic esophageal squamous cell cancer (SCR-ESCC-01)
Y Li, L Lin, J Liu, XW Cai, Q Zhang, XY Song… - Future …, 2023 - Future Medicine
This randomized phase II trial (NCT05978193) combines low-dose radiotherapy (LDRT) and
conventionally fractionated radiotherapy (CFRT) with immunochemotherapy for metastatic …
conventionally fractionated radiotherapy (CFRT) with immunochemotherapy for metastatic …
[HTML][HTML] Efficacy and toxicity of anlotinib plus camrelizumab versus anlotinib plus S-1 as second-line therapy for advanced esophageal squamous cell carcinoma: A …
W Zhang, M Chen, H Dai, W Sun - Cancer Pathogenesis and Therapy, 2023 - Elsevier
Background No data exist on the efficacy and safety of anlotinib plus camrelizumab doublet
as second-line therapy for advanced esophageal squamous cell carcinoma (ESCC) …
as second-line therapy for advanced esophageal squamous cell carcinoma (ESCC) …
